Citations

Clear

187 citation(s) found for "Ha, Gavin".

Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis
Shah, Ayesha , Jones, Michael P., Callaghan, Gavin , Fairlie, Thomas, Ma, Xiaomin, Stuart, Katherine , Cruz, Peter De , O’Beirne, James , Holtmann, Gerald , Jones, Michael , Holtmann, Gerald J , Jones, Michael P , Jones, Michael P., Culver, Emma , Tabibian, James H. , Dignass, Axel , Canbay, Ali , Gores, Gregory J.

Mayo Clinic

Hepatology Communications | January 11, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000347 | PMID 38206197 Get It

Background: Primary sclerosing cholangitis (PSC) is an immune-mediated, chronic cholestatic liver disease. Currently, liver transplantation is the only established life-saving treatment. Several studies have evaluated the effect of different biologic therapies on PSC with inconclusive findings. We conducted a systematic review and meta-analysis to assess the effects of biologics in PSC and associated inflammatory bowel disease (IBD). Methods: MEDLINE, Scopus, and Embase were searched up to July 31, 2023, for studies reporting the effects of biologics in patients with PSC-IBD. Effects of biologic therapy on alkaline phosphatase, total bilirubin, ulcerative colitis response score, and adverse events were calculated and expressed as standardized difference of means (SMD), proportions, and 95% CI using a random-effects model. Results: Six studies, including 411 PSC-IBD patients who received biologics, were included. Biologic treatment was associated with no change in alkaline phosphatase (SMD: 0.1, 95% CI: −0.07 −0.17, p=0.43), but a small and statistically significant increase in total bilirubin (SMD: 0.2, 95% CI: 0.05–0.35, p<0.01). 31.2% (95% CI: 23.8–39.7) of patients with IBD achieved endoscopic response, and there was a significant improvement in ulcerative colitis response score (SMD: −0.6,95% CI: −0.88 to 0.36, p<0.01). Furthermore, 17.6% (95% CI: 13.0–23.5) of patients experienced adverse events severe enough to discontinue therapy, and 29.9% (95% CI: 25.2–34.8) had a loss of response to biologics. Conclusions: Treatment of patients with PSC-IBD with biologics (vedolizumab, infliximab, and adalimumab) was not associated with improvement of biochemical markers of cholestasis. Biologics are effective in treating the colitis associated with PSC. Vedolizumab was associated with worsening liver enzymes in contrast to other biologics, a finding that warrants further study.
Single-Use Lens Compromise During Selective Laser Trabeculoplasty
Liu, Alice , Lyons, Lance J. , Khanna, Cheryl L. , Roddy, Gavin W. , Hodge, David O. , Sit, Arthur J. , Liu, Alice S, Sit, Arthur J

Mayo Clinic

Journal of Glaucoma | December 22, 2023 | Volume: 33 | Issue: 5 | Pages: 370-374

10.1097/ijg.0000000000002351 | PMID 38129939 Get It

Précis: Damage to disposable selective laser trabeculoplasty (SLT) lenses correlated with the amount of total laser energy. Furthermore, greater lens damage was associated with diminished patient treatment response. Purpose: Disposable SLT lenses have been observed to be damaged during use by laser, potentially affecting therapeutic response. This study sought to identify factors associated with the magnitude of lens damage and its effect on treatment outcomes. Patient and Methods: We analyzed 113 eyes from 82 patients who underwent SLT between 2020 and 2021 at an American academic medical center. For each procedure, we recorded baseline patient characteristics, procedure settings, physician age (as a possible factor causing laser defocus due to accommodation), and area of lens damage. Treatment response was calculated as the difference between preoperative and postoperative intraocular pressure (IOP). Results: Area of lens damage was associated with greater total laser energy (r=0.34, P<0.001) and greater mean energy per application (r=0.37, P<0.001). IOP reduction decreased with increasing lens damage (r=−0.19, P=0.022). Lens damage was not associated with patient characteristics indicative of glaucoma severity or user settings (physician age and slit lamp used). Greater IOP reduction was associated with higher preop IOP (r=0.46, P<0.001) and a smaller cup-to-disc ratio (r=0.22, P=0.036). IOP reduction was not associated with retinal nerve fiber layer thickness, patient age, or the number of glaucoma medications. Conclusions: Increased laser damage to disposable SLT lenses was associated with diminished treatment effect. The amount of damage was correlated with total and average laser energy, but not patient or physician factors. Overall, these findings call for reconsideration of using disposable SLT lenses as part of routine practice.
The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors
Alexander, S P H , Fabbro, Doriano , Mathie, Alistair , Peters, John A. , Veale, Emma L. , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Davies, Jamie A. , Beuve, Annie , Brouckaert, Peter, Burnett, John C. , Friebe, Andreas , Garthwaite, John , Koesling, Doris , Kühn, Michaela , Potter, Lincoln R. , Stasch, Johannes‐Peter, Alexander, Stephen P H , Mathie, Alistair A , Peters, John A , Veale, Emma L , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Davies, Jamie A , Bryant, Clare , Farndale, Richard W , Jarvis, Gavin E , MacEwan, David , Monie, Tom P , Kelly, Eamonn , Hobbs, Adrian J , Russwurm, Michael , Schmidt, Harald , Waldman, Scott A.

Mayo Clinic

British Journal of Pharmacology | December 21, 2023 | Volume: 180 | Issue: S2 | Pages: No page available

10.1111/bph.16180 | PMID 38123155 Get It

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and nearly 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16180. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
Abstract 17087: Novel Machine Learning Models to Enhance and Automate Cardiovascular Outpatient Triage for Patients With Atrial Fibrillation
Schaeferle, Gavin, Kuster, L., Jensen, Maribeth, Madhavan, Malini , Kowlgi, Gurukripa N. , Huang, Yuli

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.17087 Get It

Introduction: Atrial fibrillation (AF) is the most prevalent arrhythmia, placing a substantial burden on the healthcare system. Patients with AF are cared for in a variety of settings including primary care and cardiology clinics, while some require cardiac electrophysiology (EP) clinics offering specialized drugs or procedures. Appropriate triage of AF referrals to these specific clinics will lead to timely and appropriate care and reduce inefficiency in the health system. Goal: To develop a machine learning (ML) model to triage AF referrals to a large Cardiology center to either the Cardiology or EP clinic based on likelihood of requiring an invasive EP procedure or initiation of antiarrhythmic drug. Methods: We retrospectively analyzed 6,755 patients who were referred to CV with referral diagnosis of AF (mean age 70 ± 11 years, 66% male). We employed multiple input variables to predict the suitability for EP clinic defined as need for initiating an antiarrhythmic drug or an invasive EP procedure. These encompassed patient demographics, relevant comorbidities, medications, prior procedures, medical notes analyzed using natural language processing (NLP), and Holter monitoring data. Results: For internal referrals, XG boost model performed the best with AUC at 79%, accuracy at 72%, and F1 score at 68%. This model produces true positive (TP) at 68% and true negative (TN) at 74%, which was better in comparison with triaging using NLP only (AUC = 69%, TP = 58%, TN = 61%), Holter only (AUC = 52%, TP = 51%, TN = 77%), and NLP/Holter (AUC = 67%, TP = 60%, TN = 60%). When supplementing ML model with Holter readings on average HR ≥ 100 and maximum HR ≥ 150, the results can be improved to TP at 70% and TN at 73%. Conclusions: Our model effectively identifies patients who are more likely to require specialized EP care, enabling the automation and increased efficiency of the AF referral triage process. Prospective validation studies are paramount in determining the true value of this tool.
Wiidookaage’Win: A Community-Based Qualitative Approach to Developing a Facebook Group Intervention for Native Women to Support Recovery From Opioid Use
Young, Antonia M , Sinicrope, Pamela S. , Kelpin, Sydney S., Roche, Anne I. , Sabaque, Corinna, Pham, Cuong , Venner, K , Bastian, Emily, Nord, Teresa, Baker, Laiel, Wyatt, Thomas, Fish, A., Bart, Gavin , Young, Antonia , Sinicrope, Pamela , Kelpin, Sydney, Patten, Christi A. , Marsch, Lisa A. , Campbell, Aimee N. C. , Mason, Gail

Mayo Clinic

American Journal of Health Promotion | November 13, 2023 | Volume: 38 | Issue: 2 | Pages: 205-218

10.1177/08901171231205355 | PMID 37955409 Get It

Purpose To develop a culturally-tailored American Indian/Alaska Native (AI/AN) women’s Facebook group supporting opioid recovery as an adjunct to medication. Design Community-based, qualitative approach. Setting Minnesota, U.S. Participants AI/AN women in opioid recovery, interested parties, and a Community Advisory Committee (CAC) of AI/AN women with lived experience, health care providers, and community members. Intervention We developed evidence-based content focusing on stress/trauma and substance use, mindfulness, responding to triggers, and supportive community resources. Additional content centered on AI/AN culture was also selected. Method Interviews were conducted by two women, then transcribed and coded using content analysis with NVivo software. Results were presented to CAC for further content refinement. Results CAC members (n = 10) guided study methods, intervention development, and dissemination activities. 14 AI/AN women (mean age 36.4 years; mean 6.7 months opioid abstinence) and 12 interested parties (7 men, 5 women) were receptive to an AI/AN gender-specific Facebook group, preferring content with AI/AN people and/or text resonating with AI/AN culture (e.g., Native traditions, family, personal stories, historical trauma). Recommendations included (1) protect confidentiality, (2) retain positivity, (3) incorporate resources and exercises to build coping skills, and (4) moderators should be authentic and relatable to build trust. Conclusions Our approach provides a model for developing culturally tailored, appealing and effective social media interventions to support AI/AN women in recovery from opioid use disorder.
Abstract 145: CRISPRi-Perturb-seq In Endothelial Cells Links Atherosclerosis Risk Loci To Novel Klf2/4 Regulatory Genes
Gupta, Rajat M. , Schnitzler, Gavin R., Kang, Helen , Fang, Shi, Lee, Vivian S. , Zheng, Tony, Barry, Aurelie , Angom, Ramcharan Singh , Lee-Kim, Vivian, Ma, Rosa, Zhou, Ronghao , Mukhopadhyay, Debabrata , Engreitz, J

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.145 Get It

Introduction: Genome-wide association studies (GWAS) have discovered >300 associations for CAD. Few loci are functionally characterized and may represent new mechanisms of disease. Hypothesis: Can an unbiased transcriptional screen for the >2000 candidate GWAS genes in endothelial cells (ECs) identify causal genes and disease-relevant pathways at CAD GWAS loci. Methods: We applied CRISPRi-Perturb-seq to knock down expression of genes within 500 Kb of coronary artery disease GWAS loci (2,300 genes in total) and measure their transcriptomic effects using single-cell RNA-seq. Validation of candidate causal genes was conducted in primary human ECs and zebrafish. Results: We identified 50 programs of co-expressed genes, which represent core cellular pathways (i.e. ribosome biogenesis) and 13 EC-specific pathways such as flow response and angiogenesis. The EC-specific programs show the greatest contribution to CAD heritability. 5 EC-specific programs have the greatest number of GWAS candidate genes. We find that 43 of 306 CAD GWAS signals converge onto these 5 gene programs, and all are regulated by genes in the cerebral cavernous malformations (CCM) pathway—which coordinates KLF2/4 transcriptional responses in endothelial cells, but has not been linked to CAD risk. The strongest regulator of these programs is TLNRD1 , which we show is a new CAD gene and novel regulator of the CCM pathway. TLNRD1 loss-of-function alters actin organization and barrier function in endothelial cells in vitro , and heart development in zebrafish in vivo . Conclusions: High-throughput functional analysis of 2,300 genes proximal to CAD GWAS loci prioritized pathways—such as angiogenesis and EC migration—that are regulated by multiple risk SNPs. Our study identifies new genes that likely influence risk for CAD, identifies convergence of CAD genes into certain pathways in endothelial cells, and prioritizes study of genes in the CCM-signaling pathway for contribution to CAD risk.
Durability of intercalary endoprosthesis for humeral reconstruction
Labott, Joshua R. , Heidenreich, Mark J. , Broida, Samuel E. , Mills, Gavin L. , Rose, Peter S. , Houdek, Matthew T. , Houdek, Matthew T , Broida, Samuel E

Mayo Clinic

Journal of Surgical Oncology | September 26, 2023 | Volume: 129 | Issue: 2 | Pages: 410-415

10.1002/jso.27458 | PMID 37750341 Get It

AbstractIntroductionThe humerus is a common site of metastases and primary tumors. For some patients with a segmental defect and/or diaphyseal cortical destruction a cemented intercalary device may provide a more reliable construct, however data on their use is limited.MethodsWe reviewed 43 (28 male and 15 female) patients treated with an intercalary humeral spacer at a single tertiary referral center between 1989 and 2022. Humeral lesions were most commonly secondary to metastatic disease (n = 29, 68%), with 25 (58%) patients presenting with a pathologic fracture. Mean age and body mass index were 66 years and 27.9 kg/m2. First generation taper joint device were used in 22 patients and second‐generation lap device in 21 patients.ResultsFollowing reconstruction the 2‐year overall survival was 30%. Mechanical complications occurred in 11 patients, most commonly aseptic loosening (n = 6, 14%). With death as a competing risk, the cumulative incidence of mechanical failure was 28% at 2‐years postoperative. Following the procedure, mean Musculoskeletal Tumor Society scores was 70% and mean shoulder elevation was 87°.ConclusionReconstruction of the humeral diaphysis with an intercalary endoprosthesis provides restoration of function of the upper extremity, however, is associated with one in four patients having mechanical failure.
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial
Swisher, Elizabeth M. , Rayes, Nadine , Peterson, Christine B. , Norquist, Barbara M. , Coffin, Tara B. , Gavin, Kathleen , Polinsky, Deborah , Crase, Jamie , Blank, Stephanie V. , Olopade, Olufunmilayo I. , Law, Sherman , D’Andrea, Alan D. , Lu, Karen H. , Olopade, Olufunmilayo I , Swisher, Elizabeth M , Peterson, Christine , Norquist, Barbara , D'Andrea, Alan , Bowen, Deborah J. , Bakkum‐Gamez, Jamie N. , Munsell, Mark F. , Nebgen, Denise R. , Fleming, Gini F. , Zhou, Alicia Yiran , Levine, Douglas A.

Mayo Clinic

JAMA Oncology | September 14, 2023 | Volume: 9 | Issue: 11 | Pages: 1547

10.1001/jamaoncol.2023.3748 | PMID 37707822 Get It

Importance Requiring personalized genetic counseling may introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress. Objective To assess whether omitting pretest and/or posttest genetic counseling would increase distress during remote testing. Design, Setting, and Participants Making Genetic Testing Accessible (MAGENTA) was a 4-arm, randomized noninferiority trial testing the effects of individualized pretest and/or posttest genetic counseling on participant distress 3 and 12 months posttest. Participants were recruited via social and traditional media, and enrollment occurred between April 27, 2017, and September 29, 2020. Participants were women aged 30 years or older, English-speaking, US residents, and had access to the internet and a health care professional. Previous cancer genetic testing or counseling was exclusionary. In the family history cohort, participants had a personal or family history of breast or ovarian cancer. In the familial pathogenic variant (PV) cohort, participants reported 1 biological relative with a PV in an actionable cancer susceptibility gene. Data analysis was performed between December 13, 2020, and May 31, 2023. Intervention Participants completed baseline questionnaires, watched an educational video, and were randomized to 1 of 4 arms: the control arm with pretest and/or posttest genetic counseling, or 1 of 3 study arms without pretest and posttest counseling. Genetic counseling was provided by phone appointments and testing was done using home-delivered saliva kits. Main Outcomes and Measures The primary outcome was participant distress measured by the Impact of Event Scale 3 months after receiving the results. Secondary outcomes included completion of testing, anxiety, depression, and decisional regret. Results A total of 3839 women (median age, 44 years [range 22-91 years]), most of whom were non-Hispanic White and college educated, were randomized, 3125 in the family history and 714 in the familial PV cohorts. In the primary analysis in the family history cohort, all experimental arms were noninferior for distress at 3 months. There were no statistically significant differences in anxiety, depression, or decisional regret at 3 months. The highest completion rates were seen in the 2 arms without pretest counseling. Conclusions and Relevance In the MAGENTA clinical trial, omitting individualized pretest counseling for all participants and posttest counseling for those without PV during remote genetic testing was not inferior with regard to posttest distress, providing an alternative care model for genetic risk assessment. Trial Registration ClinicalTrials.gov Identifier: NCT02993068
Outcomes Associated With Intracranial Aneurysm Treatments Reported as Safe, Effective, or Durable
Verploegh, Iris S.C. , Satoer, Djaina , Peeters, Noëlle J. M. C. Vrancken , Sadigh, Yasmin , Vergouwen, Mervyn D. I. , Schouten, Joost W. , Bruggeman, Gavin F., Pisică, Dana, YILDIRIM, Gizem , Cozar, Ayca, Müller, F., Zidaru, Ana-Maria, Gori, Kelsey, Tzourmpaki, Nefeli, Schnell, Esther, Thioub, Mbaye , Velinov, N., Lawton, Michael T. , Dammers, Rúben , Meling, Torstein R. , Volovici, Victor , Yildirim, Gizem, Kicielinski, Kimberly , Doormaal, Pieter Jan van , Boutarbouch, Mahjouba , Lanzino, Giuseppe , Amin-Hanjani, Sepideh

Mayo Clinic

JAMA Network Open | September 1, 2023 | Volume: 6 | Issue: 9 | Pages: e2331798

10.1001/jamanetworkopen.2023.31798 | PMID 37656458 Get It

ImportanceTesting new medical devices or procedures in terms of safety, effectiveness, and durability should follow the strictest methodological rigor before implementation.ObjectivesTo review and analyze studies investigating devices and procedures used in intracranial aneurysm (IA) treatment for methods and completeness of reporting and to compare the results of studies with positive, uncertain, and negative conclusions.Data SourcesEmbase, MEDLINE, Web of Science, and The Cochrane Central Register of Clinical Trials were searched for studies on IA treatment published between January 1, 1995, and the October 1, 2022. Grey literature was retrieved from Google Scholar.Study SelectionAll studies making any kind of claims of safety, effectiveness, or durability in the field of IA treatment were included.Data Extraction and SynthesisUsing a predefined data dictionary and analysis plan, variables ranging from patient and aneurysm characteristics to the results of treatment were extracted, as were details pertaining to study methods and completeness of reporting. Extraction was performed by 10 independent reviewers. A blinded academic neuro-linguist without involvement in IA research evaluated the conclusion of each study as either positive, uncertain, or negative. The study followed Preferring Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Main Outcomes and MeasuresThe incidence of domain-specific outcomes between studies with positive, uncertain, or negative conclusions regarding safety, effectiveness, or durability were compared. The number of studies that provided a definition of safety, effectiveness, or durability and the incidence of incomplete reporting of domain-specific outcomes were evaluated.ResultsOverall, 12 954 studies were screened, and 1356 studies were included, comprising a total of 410 993 treated patients. There was no difference in the proportion of patients with poor outcome or in-hospital mortality between studies claiming a technique was safe, uncertain, or not safe. Similarly, there was no difference in the proportion of IAs completely occluded at last follow-up between studies claiming a technique was effective, uncertain, or noneffective. Less than 2% of studies provided any definition of safety, effectiveness, or durability, and only 1 of the 1356 studies provided a threshold under which the technique would be considered unsafe. Incomplete reporting was found in 546 reports (40%).Conclusions and RelevanceIn this systematic review and meta-analysis of IA treatment literature, studies claiming safety, effectiveness, or durability of IA treatment had methodological flaws and incomplete reporting of relevant outcomes supporting these claims.
Core outcomes in nerve surgery: development of a core outcome set for ulnar neuropathy at the elbow
Wilson, Thomas J. , Davis, Gavin A , Guedes, Fernando , Hébert‐Blouin, Marie‐Noëlle, Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | August 12, 2023 | Volume: 140 | Issue: 2 | Pages: 489-497

10.3171/2023.6.jns23702 | PMID 37877978 Get It

OBJECTIVE Ulnar neuropathy at the elbow (UNE) is common, affecting 1%–6% of the population. Despite this, there remains a lack of consensus regarding optimal treatment. This is primarily due to the difficulty one encounters when trying to assess the literature. Outcomes are inconsistently reported, which makes comparing studies or developing meta-analyses difficult or even impossible. Thus, there is a need for a core outcome set (COS) for UNE (COS-UNE) to help address this problem. The objective of this study was to utilize a modified Delphi method to develop COS-UNE. METHODS A 5-stage approach was utilized to develop COS-UNE: stage 1, consortium development; 2, literature review to identify potential outcome measures; 3, Delphi survey to develop consensus on outcomes for inclusion; 4, Delphi survey to develop definitions; and 5, consensus meeting to finalize the COS and definitions. The study followed the Core Outcome Set-STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 21 participants, all neurological surgeons representing 11 countries. The final COS-UNE consisted of 22 data points/outcomes covering the domains of demographic characteristics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 6 months, with the consensus optimal timepoints for assessment identified as preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The authors identified consensus data points/outcomes and also provided definitions and specific scales to be utilized to help ensure that clinicians are consistent in their reporting across studies on UNE. This COS should serve as a minimum set of data to be collected in all future neurosurgical studies on UNE. The authors hope that clinicians evaluating ulnar neuropathy will incorporate this COS into routine practice and that future studies will consider this COS in the design phase.